Relay Therapeutics, Inc. Interest Income, Other
Relay Therapeutics, Inc. (RLAY) reported Interest Income, Other of $7.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-06
- Relay Therapeutics, Inc. interest income, other for the quarter ending 2026-06-30 was $7.12M, a 0.14% increase year-over-year.
- Relay Therapeutics, Inc. interest income, other for the quarter ending 2026-03-31 was $5.35M, a 31.50% decline year-over-year.
- Relay Therapeutics, Inc. interest income, other for the quarter ending 2025-12-31 was $5.71M, a 36.37% decline year-over-year.
- Relay Therapeutics, Inc. interest income, other for the quarter ending 2025-09-30 was $6.41M, a 22.56% decline year-over-year.
- Relay Therapeutics, Inc. interest income, other for fiscal 2025 was $27.04M, a 22.19% decline from fiscal 2024.
- Relay Therapeutics, Inc. interest income, other for fiscal 2024 was $34.75M, a 11.92% increase from fiscal 2023.
- Relay Therapeutics, Inc. interest income, other for fiscal 2023 was $31.05M, a 253.35% increase from fiscal 2022.
- Relay Therapeutics, Inc. interest income, other for fiscal 2022 was $8.79M, a 958.55% increase from fiscal 2021.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.12M 10-Q · filed 2026-08-06 | $12.47M 10-Q · filed 2026-08-06 | $18.18M derived: sum of 3 quarters · filed 2026-08-06 | $24.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.35M 10-Q · filed 2026-05-05 | $11.06M derived: sum of 2 quarters · filed 2026-05-05 | $17.47M derived: sum of 3 quarters · filed 2026-05-05 | $24.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.12M derived: sum of 2 quarters · filed 2026-02-26 | $19.22M derived: sum of 3 quarters · filed 2026-08-06 | $27.04M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.41M 10-Q · filed 2025-11-06 | $13.51M derived: sum of 2 quarters · filed 2026-08-06 | $21.32M 10-Q · filed 2025-11-06 | $30.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.11M 10-Q · filed 2026-08-06 | $14.92M 10-Q · filed 2026-08-06 | $23.89M derived: sum of 3 quarters · filed 2026-08-06 | $32.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.81M 10-Q · filed 2026-05-05 | $16.79M derived: sum of 2 quarters · filed 2026-05-05 | $25.06M derived: sum of 3 quarters · filed 2026-05-05 | $33.61M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $8.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.25M derived: sum of 2 quarters · filed 2026-02-26 | $25.80M derived: sum of 3 quarters · filed 2026-02-26 | $34.75M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.27M 10-Q · filed 2025-11-06 | $16.82M derived: sum of 2 quarters · filed 2025-11-06 | $25.77M 10-Q · filed 2025-11-06 | $34.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $8.55M 10-Q · filed 2025-08-07 | $17.50M 10-Q · filed 2025-08-07 | $26.20M derived: sum of 3 quarters · filed 2026-02-26 | $34.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $8.95M 10-Q · filed 2025-05-05 | $17.65M derived: sum of 2 quarters · filed 2026-02-26 | $25.50M derived: sum of 3 quarters · filed 2026-02-26 | $33.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.55M derived: sum of 2 quarters · filed 2026-02-26 | $24.10M derived: sum of 3 quarters · filed 2026-02-26 | $31.05M 10-K · filed 2026-02-26 |
| 2023-09-30 | $7.84M 10-Q · filed 2024-11-06 | $15.40M derived: sum of 2 quarters · filed 2024-11-06 | $22.34M 10-Q · filed 2024-11-06 | $27.72M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $7.56M 10-Q · filed 2024-08-06 | $14.50M 10-Q · filed 2024-08-06 | $19.87M derived: sum of 3 quarters · filed 2025-02-26 | $21.59M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $6.94M 10-Q · filed 2024-05-02 | $12.31M derived: sum of 2 quarters · filed 2025-02-26 | $14.03M derived: sum of 3 quarters · filed 2025-02-26 | $15.03M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $5.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $7.08M derived: sum of 2 quarters · filed 2025-02-26 | $8.09M derived: sum of 3 quarters · filed 2025-02-26 | $8.79M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.71M 10-Q · filed 2023-11-02 | $2.72M derived: sum of 2 quarters · filed 2023-11-02 | $3.41M 10-Q · filed 2023-11-02 | $3.68M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.00M 10-Q · filed 2023-08-08 | $1.70M 10-Q · filed 2023-08-08 | $1.97M derived: sum of 3 quarters · filed 2024-02-22 | $2.13M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $696.00K 10-Q · filed 2023-05-04 | $963.00K derived: sum of 2 quarters · filed 2024-02-22 | $1.12M derived: sum of 3 quarters · filed 2024-02-22 | $1.30M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $424.00K derived: sum of 2 quarters · filed 2024-02-22 | $604.00K derived: sum of 3 quarters · filed 2024-02-22 | $830.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $157.00K 10-Q · filed 2022-11-03 | $337.00K derived: sum of 2 quarters · filed 2022-11-03 | $563.00K 10-Q · filed 2022-11-03 | $859.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $180.00K 10-Q · filed 2022-08-04 | $406.00K 10-Q · filed 2022-08-04 | $702.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.24M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $226.00K 10-Q · filed 2022-05-05 | $522.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.06M derived: sum of 3 quarters · filed 2023-02-23 | $2.05M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $296.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $830.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.83M derived: sum of 3 quarters · filed 2023-02-23 | $3.40M 10-K · filed 2023-02-23 |
| 2020-09-30 | $534.00K 10-Q · filed 2021-11-10 | $1.53M derived: sum of 2 quarters · filed 2021-11-10 | $3.10M 10-Q · filed 2021-11-10 | $5.02M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $998.00K 10-Q · filed 2021-08-12 | $2.57M 10-Q · filed 2021-08-12 | $4.49M derived: sum of 3 quarters · filed 2022-02-24 | $6.73M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $1.57M 10-Q · filed 2021-05-13 | $3.49M derived: sum of 2 quarters · filed 2022-02-24 | $5.73M derived: sum of 3 quarters · filed 2022-02-24 | $8.10M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.16M derived: sum of 2 quarters · filed 2022-02-24 | $6.52M derived: sum of 3 quarters · filed 2022-02-24 | $8.80M 10-K · filed 2022-02-24 |
| 2019-09-30 | $2.24M 10-Q · filed 2020-11-12 | $4.60M derived: sum of 2 quarters · filed 2020-11-12 | $6.88M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $2.37M 10-Q · filed 2020-08-27 | $4.64M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |